Metabolic research comparison

Semaglutide vs Tirzepatide vs Retatrutide

Compare receptor targets, research focus, evidence context and live catalog data without turning the table into a recommendation.

Comparison point	Semaglutide MedCore	Tirzepatide MedCore	Retatrutide MedCore
Research mechanism	GLP-1 receptor agonism.	Dual GIP and GLP-1 receptor agonism.	GLP-1, GIP and glucagon receptor agonism.
Current catalog formats	Semaglutide MedCore 20mg — €189.00 Semaglutide MedCore 10mg — €105.00	Tirzepatide MedCore 20mg — €199.00 Tirzepatide MedCore 10mg — €109.00	Retatrutide MedCore 20mg — €239.00 Retatrutide MedCore 10mg — €139.00
Current EUR price	€105.00	€109.00	€139.00
Research focus	Incretin and metabolic signaling research.	Dual-incretin signaling research.	Triple-agonist metabolic signaling research.
Evidence context	A substantial clinical literature exists for approved semaglutide medicines; this catalog entry remains research-only.	Clinical evidence exists for approved tirzepatide medicines; conclusions must remain tied to studied products and settings.	Retatrutide remains investigational; its evidence base is still developing and does not support a catalog recommendation.

Current catalog entries

Semaglutide MedCore in a pre-filled pen format. 10mg and 20mg variants, 98% purity and CoA/HPLC documents. For research purposes only.

€105.00

Tirzepatide MedCore in a pre-filled pen format. 10mg and 20mg variants, 98% purity and CoA/HPLC documents. For research purposes only.

€109.00

Retatrutide MedCore in a pre-filled pen format. 10mg and 20mg variants, 98% purity and CoA/HPLC documents. For research purposes only.

€139.00